Skip to main content
Clinical Trials/NCT05214365
NCT05214365
Recruiting
Not Applicable

Physiological Pacing vs.Conventional Pacing in the Prevention of Pacemaker-induced Cardiomyopathy: A Randomized Study

Hospital Clinic of Barcelona1 site in 1 country200 target enrollmentFebruary 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Conduction System Pacing
Sponsor
Hospital Clinic of Barcelona
Enrollment
200
Locations
1
Primary Endpoint
Compare the incidence of pacemaker-induced heart disease
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The implantation of a pacemaker and conventional cardiac pacing from the right ventricle (apex or septum) is an effective and safe therapy for the treatment of patients with atrioventricular block and bradycardia.

Detailed Description

Pacemaker implantation and conventional cardiac stimulation from the right ventricle is an effective and safe therapy for the treatment of patients with atrioventricular block and bradycardia. But it can cause worsening of heart function, with a significant drop in LV ejection fraction, known as pacemaker-induced cardiomyopathy (PICM). Conduction system pacing (either by his or left bundle branch pacing) causes a physiological left ventricular activation through the normal conduction system thus correcting the electrical and mechanical asynchrony caused by conventional pacing. Conduction system pacing may prevent the appareance of PICM. Clinical, electrocardiographic, echocardiographic follow-up will be performed for 1 year.

Registry
clinicaltrials.gov
Start Date
February 1, 2022
End Date
September 1, 2026
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Josep Lluis Mont Girbau

Head of Arrhythmia Section. Professor of Cardiology

Hospital Clinic of Barcelona

Eligibility Criteria

Inclusion Criteria

  • The patient must be ≥ 18 years of age.
  • The patient must indicate their acceptance to participate in the study by signing an informed consent document.
  • Patients with EF\> 50% and indication for pacemaker implantation due to atrial-ventricular block according to current clinical guidelines.

Exclusion Criteria

  • Inability to understand and sign the informed consent.
  • Patients with severe comorbidities and life expectancy \<1 year.
  • Patients with severe cognitive impairment or other comorbidities resulting in dependence for basic activities of daily life.
  • Patients who cannot come to our center to carry out the follow-up of the study.

Outcomes

Primary Outcomes

Compare the incidence of pacemaker-induced heart disease

Time Frame: 12 months

Pacemaker induced cardiomyopathy defined as appearance of ventricular dysfunction LVEF \<45% or admission due to heart failure.

Secondary Outcomes

  • Correction of septal flash.(12 Months)
  • Total implantation and electrode implantation times.(12 Months)
  • Change in end-systolic volume.(12 Months)
  • The Quality of Life Scale.(12 Months)
  • NT-proBNP.(12 Months)
  • Incidence of new onset of atrial fibrillation.(12 Months)
  • Adverse events.(12 Months)
  • Hospitalization due to heart failure.(12 Months)
  • New York Heart Association functional classification.(12 Months)
  • Pacing thresholds.(12 Months)
  • Six minute walking test.(12 Months)

Study Sites (1)

Loading locations...

Similar Trials